Women’s Health Just Got Promoted
Blog Posts
Posted by Bowdoin on July 22, 2026
Women’s Health Just Got Promoted
Katelyn Marini, Partner, The Bowdoin Group | July 22
We’ve all sat through more women’s health panels than we can count, and they all used to hit the same drum: “did you know menopause is hard?” Yes. We knew. Every woman on your leadership team knew.
But what’s happened in the last 30 days is an entirely different animal.
Investors wrote nine-figure checks. A federal regulator reversed 20 years of its own policy. And women were named CEO or president at health systems across the country, all in the same news cycle, none of it coordinated. When capital, regulation, and leadership all move in the same direction at the same time without anyone planning it that way, that’s usually not a trend. That’s the market quietly finishing a decision everyone else is still debating.
1. The Investment: It’s Moving Beyond Just Wellness Capital
Hormonal health platforms raised $117.6 million across six deals over the past year, led by Midi Health’s $100 million Series D. But the more interesting shift is not the size of the check. It is the story being used to earn it. These companies used to lead with empowerment. Now they are leading with retention, productivity, healthcare costs, and employer ROI. That is the tell: women’s health is no longer being pitched only as a consumer wellness category. It is increasingly being sold as workforce infrastructure.
Here is the number worth memorizing before your next budget conversation: Mayo Clinic researchers estimated that menopause symptoms cost the United States $1.8 billion annually in lost work time, a figure that rises to $26.6 billion when associated medical costs are included. That is not a wellness line item. It is a productivity leak with a receipt attached.
2. The Innovation: The FDA Said the Hard Part Out Loud
The FDA is removing the black box warning that’s shaped hormone therapy prescribing for two decades, a warning based on a study where the average patient was 63, more than a decade past typical menopause onset, using a formulation nobody prescribes today. FDA Commissioner Makary didn’t soften it: “tens of millions of women have been denied the life-changing and long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk.”
Translated out of regulator-speak: yes, a federal agency just confirmed that two decades of standard medical practice ran on a statistical error, and an entire generation of high-performing women were told their symptoms were “just aging” as a result. That’s not a footnote. That’s a two-decade miscalibration in exactly the population most likely to be sitting in your leadership pipeline right now. Meanwhile the innovation curve is racing past hormones entirely, toward cardiovascular risk scoring and diagnostics that analysts estimate could add $28 billion a year to the economy by 2040. The sector isn’t just getting funded. It’s getting corrected.
3. The Leadership: We’re Watching Who’s Rising To The Top
While that money has been moving, women are also being named CEO or president at hospital systems and health networks nationwide; Legacy Health, Texas Health Resources, Beacon Health System, several more, all within a few weeks of each other. Meanwhile, plenty of boards outside healthcare are still treating “add a woman” as the finish line rather than the starting gun.
Here’s the connection nobody’s saying out loud: the same industry that just admitted it under-treated women medically for two decades is also the industry currently putting more women in charge of running things than almost anyone else. That’s not a coincidence. That’s what happens when an industry gets forced to look directly at its own blind spot instead of scheduling a panel about it. The question for every other sector: are you going to wait for your own regulatory reckoning before your bench looks like this?
One Honest Caveat You Need To Be Aware Of
There’s a real, organized counter-argument gaining traction, pointing out that women’s health already receives 2–3x the NIH funding of men’s health, and seven dedicated federal offices to men’s zero. Worth knowing before it shows up as a “well, actually” in a room you’re in. The strongest response isn’t a louder moral case, it’s the balance sheet: a documented 20-year clinical policy error and $26.6 billion in annual productivity loss aren’t ideology. They’re arithmetic.
Bowdoin’s Bottom Line
Money doesn’t do diligence on culture. Regulators don’t read pitch decks. Boards don’t consult the FDA before naming a CEO. And yet all three moved the same direction in the same month, entirely independently. That kind of alignment doesn’t happen by coincidence, it happens when a market has already made up its mind and everyone else is just catching up on the paperwork.
The organizations paying attention now will build their bench and their benefits strategy ahead of the curve. The ones that wait will be explaining the gap in twelve months, in a board meeting, after losing someone they didn’t have to lose, and no panel is going to fix that after the fact.
– Katelyn Marini
P.S. If your leadership bench does not yet reflect where the market is heading, let’s talk while it’s still a strategic conversation, not a moment of panic.